Anika Therapeutics (ANIK) Change in Accured Expenses (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Change in Accured Expenses of $265000.0 for Q2 2026, up 112.25% year-over-year from $124851.9 in Q2 2025, and up 119.79% quarter-over-quarter from -$1.3 million in Q1 2026.
Anika Therapeutics (ANIK) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Change in Accured Expenses for 17 consecutive years, with $265000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Accured Expenses rose 112.25% year-over-year to $265000.0; the TTM figure through Jun 2026 stood at $2.7 million (up 167.16% YoY), while the FY2025 annual figure was -$1.5 million, up 59.12% from the prior year.
- Change in Accured Expenses climbed to $265000.0 in Q2 2026 per ANIK's latest filing, from -$1.3 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $4.6 million in Q3 2023 and bottomed at -$4.3 million in Q2 2023.
- Historically, Change in Accured Expenses has averaged -$279888.9 across 5 years, with a median of -$208500.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 255.3% — and 2024, when it tumbled 567.67%.
- Anika Therapeutics' Change in Accured Expenses stood at -$558000.0 in 2022, then jumped by 231.54% to $734000.0 in 2023, then tumbled by 227.38% to -$935000.0 in 2024, then surged by 115.08% to $141000.0 in 2025, then soared by 87.94% to $265000.0 in 2026.
- Business Quant data shows ANIK's Change in Accured Expenses at $265000.0 in Q2 2026, -$1.3 million in Q1 2026, and $141000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 265,000.00 |
| Jun 30, 2026 | 265,000.00 |
| Mar 31, 2026 | -1.34 Mn |
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | 141,000.00 |
| Dec 31, 2025 | 141,000.00 |
| Sep 30, 2025 | 3.61 Mn |
| Sep 30, 2025 | 3.61 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Jun 30, 2025 | -2.16 Mn |
| Mar 31, 2025 | -3.09 Mn |
| Mar 31, 2025 | -3.09 Mn |
| Dec 31, 2024 | -935,000.00 |
| Dec 31, 2024 | -935,000.00 |
| Sep 30, 2024 | 2.20 Mn |
| Sep 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | -1.82 Mn |
| Jun 30, 2024 | -1.82 Mn |
| Mar 31, 2024 | -3.11 Mn |
| Mar 31, 2024 | -3.11 Mn |